Cancer Drugs

Jim Shannon Excerpts

Tuesday 19th January 2016 Westminster Hall

[Jim Shannon (Strangford) (DUP)]

Thank you, Mr Streeter. You have put me on a sticky wicket. I congratulate the hon. Member for Mid Derbyshire (Pauline Latham) on securing this debate. It is good to be here and to be involved. About six months ago, I had a similar debate on the availability of cancer drugs, at which I think she was present. We hoped that six months later we might be back to say that things were better or had advanced, but unfortunately that is not so, or not in the way that we would like.

I would just like to mention the many organisations that are helpful, because every one of us will have some cancer organisations close to their heart. Mine are Cancer Research UK, Macmillan Cancer Support and Marie Curie, because I have a very good friend, Irene Brown, who is terminally ill and she is in the Marie Curie centre in Belfast. The treatment that Marie Curie gives is second to none, and people only have to be there to be part of that family that helps.

The Macmillan charity says that 2.5 million people in the UK were living with cancer in 2015. It says that 5% of our total adult population are affected, which shows the problem is enormous. For many of us, cancer is not simply something that others talk about; it is something that affects each and every one of us every day. My father was a survivor of cancer on three occasions. I put that down to the skill of the surgeon, the prayers of God’s people—something that many of us here would understand—and the care of the nurses. He survived and lived for another 36 years, dying just last year, at the ripe old age of 85. The marvellous steps that modern medicine has taken are fantastic.

Moves such as the removal of drugs prevents thousands of cancer sufferers across England and Wales from being able to access the quality treatment they deserve. Thousands of people are disadvantaged, thousands of people lose out and thousands of normal people are in despair. That is the reality of not having access to cancer drugs. I do not know what it is, but I have more people coming to my office suffering from cancer than I can ever recall. I know that there is a 50% survival rate today for those with cancer, which is fantastic—what a step forward—but I see more people with cancer than ever before. I am not sure whether it is due to diet or lifestyle, or whatever it is, but cancer is certainly a greater issue for me than ever.

[David Simpson (Upper Bann) (DUP)]

We understand that, from April, NICE will have the overall say on what drugs and treatments people will receive. We know that we have to be prudent with money, but surely finance should not be the overriding factor when it comes to people’s lives.

[Jim Shannon]

I thank my hon. Friend for saying that. Over the last few months and before Christmas, I had the opportunity to meet some of the pharmaceutical companies, and I have to say—and to be careful what I say—that they are not terribly happy with NICE and how it has responded to them. Some of those pharmaceutical companies have reduced their prices and still NICE does not respond in the positive fashion that we would expect it to. That is one of my concerns, certainly.

I would put Queen’s University Belfast up there as one of the universities working in partnership with medical companies, including companies from China and from across the United Kingdom. The partnerships that the university has developed and the innovative drugs that it is coming up with, as well as the investigations and trials that take place there to find new drugs, are impressive. We have new developments in Northern Ireland in cancer research, and we need to see a national strategy. Perhaps the Minister could respond to that point—let me apologise to him again, having already done so beforehand, for not being here for his response to the debate.

My party colleague Simon Hamilton is a Member of the Legislative Assembly and the Minister for Health, Social Services and Public Safety. Health is a devolved matter in Northern Ireland. We have a number of Members from Northern Ireland—there are five here today—which shows the interest in this issue in Northern Ireland. Simon Hamilton has taken the initiative to release £1.5 million to fund specialist cancer drugs. That will allow some of the NICE-approved cancer drugs and treatments to go ahead this year.

That move in Northern Ireland will go some way towards enabling the health service there to reach the cancer target. Each day in Northern Ireland, 23 people are diagnosed with cancer and 11 people die of it. There were more than 331,000 new cases of cancer in 2011 across the United Kingdom, and 161,823 deaths from cancer in 2012. The enormity of cancer—how it afflicts people and how many people die—cannot be underlined enough.

The latest delisting of drugs from the Cancer Drugs Fund looks like a step back rather than a step forward in the fight against cancer. I know that we cannot be completely resistant to change—the Minister knows that and, as elected representatives ourselves, we also know it. If drugs are proving ineffective, they should be delisted, but at the same time, if drugs are effective, let us get them on the list and make them available to those who need them most. We should be here to commend, I hope, the addition of a new form of effective treatment.

To conclude—I am very conscious of what you said earlier, Mr Streeter—the hon. Member for Mid Derbyshire mentioned Abraxane, and here is the postcode lottery. Those living in Northern Ireland do not have any access to Abraxane whatsoever. Those living in England had access to it in March 2014, but not now. People in Scotland have had access to Abraxane since January 2015 and will still have it. In Wales, people have been able to access it since September 2014, but now it looks like that might be affected as well. That is the postcode lottery for cancer drugs. It is completely unacceptable, and I commend the hon. Member for Mid Derbyshire for securing this debate.

Space Policy

Jim Shannon Excerpts

Thursday 14th January 2016 Commons Chamber

[Jim Shannon (Strangford) (DUP)]

It is a pleasure to speak in this debate and to hear the other contributions.

It is always a pleasure to hear the hon. Member for Central Ayrshire (Dr Whitford). I look forward to hearing her speak about health issues, because she brings her wealth of knowledge to the House. Her contributions are always well worth listening to because we learn from them. That is why I enjoy them and I want to thank her. We have found out today that her knowledge goes beyond health issues: it extends to space policy and to places where no man has gone before.

Here we are in the Chamber with the chance to speak about this issue. It is always very nice to see the Minister in his place. I think that I can honestly say, without fear of contradiction, that if the Minister is in the House, I will be on the other side ready to ask him a question, and vice versa.

It is always good to consider this important and too often overlooked issue. Although it is not pertinent to Northern Ireland at the moment, I want to make sure that the Province is part of the Government’s strategy for the space sector. That is why I wanted to make a contribution. I want to put down a marker for Northern Ireland and to ensure that we have the chance to be part of the strategy.

Northern Ireland has one of the youngest workforces in the United Kingdom of Great Britain and Northern Ireland, as the Minister will know. We have a lot of well-educated young people with high skill sets who would benefit from jobs in the space sector. I believe that that would go some way to addressing the brain drain in Northern Ireland. Although that is declining, it is something that we need to get to grips with.

Perhaps in his response, the Minister will tell us how the space policy can interact with Northern Ireland. How can we get some of the benefits and spin-offs of it? How can we be part of the strategy of the United Kingdom of Great Britain and Northern Ireland? We are better together, as he would say. It is good to see all the Members who are in the Chamber, united within the United Kingdom of Great Britain and Northern Ireland.

[Mr Angus Brendan MacNeil (Na h-Eileanan an Iar) (SNP)]

Will the hon. Gentleman give way?

--- Later in debate ---

[Jim Shannon]

I am very happy to give way, although I will probably regret it.

[Mr MacNeil]

The hon. Gentleman will be aware of the press stories today mentioning Stornoway. Indeed, the name David Bowie is linked with it as well. Just a little bit north of Malin Head, the hon. Gentleman will see the Outer Hebrides. It is a fantastic place—near Northern Ireland—for such space adventures.

[Jim Shannon]

Earlier, the hon. Gentleman was waxing lyrical about black puddings; now he is doing the same about Stornoway in a different way. It is always good to hear from him.

[Mr MacNeil]

Black puddings in space!

[Jim Shannon]

Absolutely.

Ensuring that the space sector has a place in Northern Ireland and is aware of what we have to offer will go some way towards addressing the brain drain issue of too many of our young people emigrating. I would like to hear from the Minister how the space policy can better connect with Northern Ireland.

Northern Ireland has a proud history of air flight, although it is not linked directly to space policy. Henry George Ferguson, who was better known as Harry, a brother Orangeman, was a Northern Ireland engineer and inventor who was noted for his role in the development of the agricultural tractor. He was also the first Ulsterman and Irishman to build and fly his own aeroplane. The first ever airport in Northern Ireland was in my constituency of Strangford, in Newtownards, and was built in about 1910.

Northern Ireland has a fantastic aerospace industry with Magellan and Bombardier, which has been established for many years. I believe that there is a role for those aircraft companies to play in space policy and development. They can and should be part of it.

The space sector is fundamental to the future UK economy. I welcome the Government’s civil space strategy and the goal that the space sector will contribute £40 billion a year to the UK economy by 2030.

[Dr Philippa Whitford]

The point that I was trying to make in my opening speech was that the bid talks about a UK spaceport, whereas I think there will be different sectors. One sector that will come in the not-too-distant future is hyperbolic sub-orbital flight. Once we get past the Virgin Galactic model of a plane and a wee rocket, we will have the combination of jet and rocket engines, such as SABRE—the synergistic air-breathing rocket engine—which will go from standstill to orbit and back down. We will be able to fly to Japan in a short period of time. Different sites around the UK may therefore follow totally different routes. That should be enabled, not blocked.

[Jim Shannon]

I thank the hon. Lady for that significant and important intervention. She shows the vision that all of us in this House should have. There are no barriers to what we can do. Some of the things that are in “Star Trek” are not impossible, so let us look forward to those developments. I look forward to being able to travel from A to Z—from Belfast City to Heathrow—in a matter of seconds. If that is ever possible, we will be able to get here and back a couple of times and to do business at home and here, all in the same hour. Is that possible? I do not know, but I hope it will happen.

Thinking back on how space has been discovered, I am always mindful of the first time man stepped on the moon. It was one small step for man, one giant leap for mankind. For me, and I think for many others, that showed us the immensity and size of the universe that God created, and it focused our minds on God’s power and the fact that it was not for us as children, and that he is in total control of the universe.

[Mr MacNeil]

The hon. Gentleman quoted the historic phrase, “One small step for man, one giant leap for mankind”, but what about the seriousness with which the space industry considered the Isle of Man a number of years ago? Those in the know in the space industry said that only the United States, Russia, China and India were ranked above the Isle of Man for the likelihood of getting the next person on the moon. That shows that if the political will is there, a lot can be achieved.

[Jim Shannon]

I thank the hon. Gentleman for his intervention. We should believe in what we want to achieve, and that goal is achievable if we are determined to make it happen.

The Deregulation Act 2015 is an encouraging development that will allow the UK to be more competitive globally in this future industry. It is important to consider that and to ensure that we are world leaders in offering somewhere for the space industry to do business. We want to be part of that business across the United Kingdom of Great Britain and Northern Ireland. The 2010 space innovation and growth strategy is another welcome development that seeks to create a partnership between industry, Government and academia to develop, grow and make use of new space-related opportunities.

This debate is important because of the possibilities of what can be achieved, which enthuse us all. Although there were encouraging developments during the last Parliament, it is disappointing that space did not receive a mention in the Government’s 2015 manifesto. I am sure that the Minister will correct that when he responds, and clearly set out Government policy and strategy. I hope this is not a sign of the Government taking their eye off the ball.

The Government are hoping that the new regulatory framework enabled by the Deregulation Act will allow the creation of a commercial spaceport in the UK by 2018—again, a marvellous vision of what can happen in future. That is a welcome development because commercial space travel is an industry in which we can, quite literally, reach for the stars. In “It’s a Wonderful Life”, James Stewart talked about lassoing the moon. We are not going to lasso the moon; we are going to reach it and beyond, and it is important that we have that possibility.

The value of the space sector in the UK has grown from £6.5 billion in 2007 to £11.8 billion in 2014—it has almost doubled, and there is the potential for it to double again. With Tim Peake’s recent mission sure to rekindle interest in the space industry, that trend is sure to continue, and the ability to offer commercial space travel will make us world leaders in the space industry.

[Dr Lee]

I do not know whether the hon. Gentleman remembers this, but he was one of the few Members of the House who attended my Adjournment debate on microgravity. Prior to that I had been contacted primarily from America by Boeing and various other companies on the subject. They pointed out that the microgravity research industry had a potential $100 billion of growth. The hon. Gentleman is right to point out the future potential for the space industry.

[Jim Shannon]

I do remember that. It was one of those Adjournment debates that I am known to attend, and I remember intervening along those lines. It was three or four years ago.

Something else that I enjoyed, and that I think was positive, took place last week when Tim Peake was able to make radio contact with young people in a school. The inspiration that that gave to those young people was fantastic, as was the fact that it happened. Those young people were inspired, and they had a photograph and a TV show that showed him in their school making direct contact. I know it was a bit rehearsed, but it was exciting for us to watch. How much more exciting must it have been for the children, both male and female, to have that ambition and inspirational drive to try to be the next Tim Peake in space? As we seek to obtain secure jobs for the future, we need more such encouraging developments, and this has been a welcome opportunity to contribute to a debate on an issue of great importance to the future of our country and its economy.

In conclusion, the new national space policy, the Deregulation Act, and the space innovation and growth strategy are all signs that we are heading in the right direction. The positivity that comes through this debate will be noted not just in this Chamber by MPs, but outside the House and further afield. We can play our part in space travel and policy in future, and I hope that off the back of this debate we can maintain momentum and ensure that those plans turn into real delivery for the “better together” space industry and future economy of the United Kingdom of Great Britain and Northern Ireland.

--- Later in debate ---

[Mr Iain Wright (Hartlepool) (Lab)]

It is a pleasure to contribute to this debate. I congratulate the hon. Members for Central Ayrshire (Dr Whitford) and for Glasgow North (Patrick Grady) on securing it and I thank the Backbench Business Committee for agreeing to it. There have been far too many references to “Star Trek” at the expense of “Star Wars”, so let me try to even it up a bit. Space policy has not been debated as much as it should have been in this House given how important it is, but I am pleased that, as a result of the tenacious attitude of the hon. Members for Central Ayrshire and for Glasgow North, the force has awakened. [Laughter.] That’s the only thing you’re going to get.

As has been mentioned, Tim Peake’s mission on the international space station is a fantastic achievement. I think the whole House and the whole country wish him well as he embarks on his spacewalk tomorrow. His mission is important for a number of reasons. First, he is undertaking practical experiments and research that will have positive applications back on earth, a point to which I will return in a moment. Secondly, as has already been mentioned, Major Peake’s space mission is undoubtedly inspiring and motivating a whole new generation, rather like a previous generation was inspired by the Apollo programme. I remember the inspirational words of President Kennedy:

“We choose to go to the moon…and do the other things, not because they are easy, but because they are hard”.

That inspiration and ambition are incredibly important.

The young people looking at what Major Peake is doing—following his journey and progress on Twitter, Facebook and so on, and perhaps even interacting with him as he conducts experiments in space—will have their eyes opened to the enormous and often unlimited potential available to them in their lives and careers. They might not necessarily want to become astronauts—I still have a wish to be an astronaut; I think everyone in this debate does—but they will see the dizzying potential and scope of science, technology and engineering. I hope that the impact of Tim Peake’s mission into space will last for decades, as young people are inspired to go on to have an impact on science and research throughout the 21st century.

The third reason why Major Peake’s mission is so important is that it showcases a true British industrial success: the UK space industry, and that is what I want to focus on. Most people walking the streets today will not be aware, as the hon. Member for Central Ayrshire said, that Britain has a space sector. People will perhaps automatically think of NASA and, possibly, Russia. They might consider a space industry linked with putting people regularly into space or, as the hon. Member for Glasgow North said, with missions such as New Horizons and the exploration of Pluto and the Kuiper Belt. Major Peake’s journey gives us the opportunity to celebrate a great British economic success and highlight what I hope is a shared ambition—it certainly is in today’s debate—to see the sector grow.

I think the Minister would agree that the UK space sector is the very model of the type of modern, successful sector that Britain should be focused on: innovative and high value, and providing well-paid and highly rewarding —in every sense—careers. It taps into Britain’s strengths, based on the very best of science, engineering and world-class British research, but with a very clear nod to British excellence in professional services, such as legal, financial and regulatory work. It is a rapidly growing sector throughout the world—perhaps it is best to say above the world—and the British comparative advantage should be used to capture even more wealth and value for this country in the future.

We have been quite canny in this country in identifying precisely where in the space sector, and throughout its value chain, Britain excels. We have skills in upstream activities, such as satellite construction. I visited Airbus in Stevenage and saw the great work that goes on there. I saw satellites being built and walked on the surface of “Mars”, which was absolutely fantastic. Our real strength and potential, however, lie in the industry’s downstream activities, such as user equipment, applications, services and data. Our strengths in professional services such as legal, regulatory and financial services allow Britain to lead the world in raising capital to finance space technologies, as well as the expertise to provide licensing arrangements. It is these downstream activities that will increase demand in the future so that Britain is well placed for future growth.

The hon. Member for Central Ayrshire and others have already mentioned the figures, but it is important to reiterate just how successful the UK space sector has been in recent years. It generates almost £12 billion for the UK economy, which is almost double the value of the sector just a short time ago in 2007. The industry directly employs 37,000 people in this country. That figure rises to 115,000 when one considers the supply chain, and supported and indirect jobs. UK space has seen an annual growth rate of 8.6% since 2008-09.

Madam Deputy Speaker, I think you were in the Chair yesterday when we discussed, in an Opposition day debate secured by the Scottish National party, some of the structural weaknesses in our productivity and trade positions. Frankly, if all other sectors in the British economy were performing at the same rate as the UK space industry, this country would be doing well. Productivity is three times the national average, with a value added of £140,000 per employee in the sector. Exports are twice the national average, representing about a third of the sector’s turnover. That success bodes well for the future. The global space industry is set to grow even further to about £400 billion by 2030. The UK space sector’s ambitions are challenging but achievable; the national space policy’s objectives are for Britain to have a 10% market share in the global space industry, provide £40 billion of value to the British economy and employ an additional 100,000 workers by 2030.

I hope there is a real consensus across the House, regardless of party affiliation, for that ambition, and for backing the Government and building on the back of previous support for UK space, regardless of which party is in government. Tribute must be paid to Paul Drayson, who launched, as it were, much of the Government’s interest in UK space. To be fair, David Willetts continued that policy in an excellent way throughout the coalition Government, providing all-important policy continuity and certainty that transcended Parliaments, and allowed confidence in the sector to grow and gave potential investors the reassurance that has provided much of the success for British space.

Given the characteristics of the UK space sector—a high-value, innovative, productive, export-focused industry that has identified our specific key strengths within the sector and built on that comparative advantage to secure more global market share in the future, assisted by a strong and long-standing partnership between industry, Government and research to provide policy certainty—it is surprising that the Government do not want to shout more about the virtues of an industrial strategy. An industrial strategy has been part of the success of the UK space industry. The Secretary of State seems to have abandoned such aspirations, with the possible exceptions of the aerospace and automotive industries. That seems wrong. I am pleased that the Minister on the Treasury Bench is the Parliamentary Under-Secretary of State for Life Sciences. I would single out life sciences as another great skill for Britain. It is a marvellous sector, so why is it not also classed as strategically important? That approach is very important.

In his autumn statement, the Chancellor announced a movement of research funding away from grants to loans, with the exception of the aerospace and automotive sectors. That runs the risk, as mentioned yesterday, of investment not being attracted to Britain. For such a successful and promising sector as space, that is worrying. Will the Minister consider expanding the definition of the aerospace sector to include space so that it can take advantage of the security of research funding and grants?

[Jim Shannon]

In seeking to advance the space industry, is it not important to involve universities and their expertise and knowledge? Is partnership with universities not also part of this?

[Mr Wright]

That is incredibly important. Britain’s unique blend of strong leadership and partnership between industry and Government, through things such as the UK Space Agency and the Space Leadership Council, and our world-class research expertise and strong university base, means we are well positioned to capture as much market value as possible.

Will the Minister accept—I believe he personally believes it—that industrial strategy works and commit to ensuring that the Government embrace such an approach so that sectors such as space and the life sciences can be exploited as much as possible for the benefit of Britain? I mentioned that the national space policy set out an ambition for 100,000 additional jobs in the space industry in the next 15 years—I think we would all sign up to that—but given the skills shortages in engineering and science-based industries throughout the economy, and the difficulty of encouraging girls and young women to consider science, technology, engineering and maths subjects in school, college and university and then as a career, what is he doing to address barriers to growth in the UK space sector? What further assistance, in terms of outreach activities, internships and apprenticeship opportunities, will be provided to motivate and inspire girls and young women to think about a career in space?

In criticising the space industry, it is often said that interest and investment in space is a luxurious folly and that, at a time of austerity and crisis in public services, we cannot afford a space industry: why are we sending a man into space, when patients are lying in hospital corridors? This is a false argument. To a vast extent, the UK space industry is driven by private sector investment—Government investment in the past 15 years has averaged 0.015% of total investment—and the value it creates grows the economy, employs people on good wages and increases tax revenues, thereby helping to fund public services. Research in space or in the space industry has positive applications on earth—for example, satellite technology and food crops or experiments into materials and how they react. Major Peake, while on the international space station, is carrying out experiments to measure pressure in the brain that could have important applications in serious trauma care. Investment in space results in tangible benefits for society on earth.

I am not just talking about the cost-benefit analysis. I was struck by the comments of the hon. Member for Bracknell (Dr Lee). Industry is important, and the bottom line is crucial, but as he said, exploration and imagination are fundamental to the human spirit, and it is difficult to think of anything comparable to space when it comes to letting our imaginations run riot. It is vital that we ensure an interest in space by showing what space can provide. The UK space industry is a huge success story, and has the potential to grow still further and inspire a whole generation, but that requires an ongoing partnership between industry, the Government and research. This debate shows that there is great consensus and that many people support the Government in ensuring that the UK space industry realises its potential.

[Drew Hendry (Inverness, Nairn, Badenoch and Strathspey) (SNP)]

I have much to thank my hon. Friends the Members for Central Ayrshire (Dr Whitford) and for Glasgow North (Patrick Grady) for. Anyone observing me in the Chamber today will have seen me smiling broadly all the way through this debate. It is an incredibly exciting opportunity. I remember, as a young child, playing with my Airfix kit of the Apollo 11, with its detachable parts and so on, seeing how it all worked, so it is exciting to be in the Chamber today discussing the future of space policy—there it is, up on the annunciator; what an opportunity! It is just a shame there is so much space on the Benches—but I will try to avoid the puns and conduct myself with gravity.

I want to talk about the exciting opportunities out there. Yesterday in the Chamber, we discussed trade and industry and innovation, and again I want to talk most today about innovation and the skills required. There are so many wonders in space and so many things we can learn that we cannot comprehend at the moment. Without the investment that hon. Members, including the hon. Member for Hartlepool (Mr Wright), have talked about, and without making sure we can learn those things, how can we hope to take full advantage of the opportunities to develop ourselves as a race? There are stars out there 1,500 times bigger than our sun, and how much do we know about them? 3c303 is a galaxy with a black hole in the middle of it that has the biggest electrical current ever detected in the universe. There are fantastic opportunities to find out how that happens. What can we learn from that about how we conduct our lives and protect our planet into the future? I was stunned to find out there was a gigantic raincloud out there, floating in space, that is not just the size of the Pacific ocean, but 100,000 times larger than the sun. It is an amazing thing to comprehend, but we do not know enough about these things. We have to invest.

The Scottish Government see huge potential for the space industry in Scotland, and we are pleased that the UK Government and the Civil Aviation Authority do too. We should be exploring these opportunities jointly. The Scottish Government have committed to supporting science and technological development in education and industry, having recognised science’s contribution to a sustainable economy. The hon. Member for Hartlepool talked about opportunities. The space industry, 16% of whose employees are in Scotland, is growing by 7.5% a year. These are encouraging figures, but we must do more. There is a recruitment exercise to ensure that there are members to join the Scottish Science Advisory Council. The Scottish Government have engaged with the world-leading science sector on the post of chief scientific adviser for Scotland and are currently advertising for the post, which is the right thing to do just now. They are continuing to invest in four science centres and to support science festivals in Scotland. They continue to promote the value of science as a career for young people.

In my previous career as a councillor in the highlands, I was passionate about getting our young people interested and encouraging them to lift their sights and see the opportunities available, not just to us as a set of countries on these isles but to them. There are rewarding and meaningful careers and they can build something important for themselves. As a new councillor eight years ago, I saw an advert put out by the European Space Agency calling for the next generation of recruits to come forward. As an enthusiastic councillor, I thought I would put out a press release across the highlands saying, “Young highlanders should come forward.” I was disappointed that it was met with scepticism from my colleagues on the council. They thought it was a mad idea to encourage highland children to get involved in the space industry. I was desperately disappointed by their attitude, but it highlighted to me the need to change people’s attitudes to these opportunities and how they could take advantage of them.

I am pleased to say that one development from that is the science skills academy, which is starting up in the highlands. It is a collaborative enterprise that brings together organisations such as Highlands and Islands Enterprise, the Highland Council and a range of private businesses and engineering firms, as well as other non-governmental operatives in the highlands. It aims to encourage young people from pre-school, throughout their education and beyond, to take advantage of the opportunity of gaining these skills, which directly transfer not just into the aerospace industry but to and from oil and gas, renewables and so forth. These are similar skill sets that can be transferred across. Embracing this into the future provides enormous opportunities. I hope that future attitudes in the highlands will be changed, but there is a job of work to be done in this Chamber, in the Holyrood Chamber and in all the devolved Administrations to make sure that we get the word out to our young people to raise their sights and look for an opportunity.

I am grateful to my hon. Friend the Member for Central Ayrshire for telling us that Helen Sharman was the first astronaut from Britain in space. It is important to repeat that message because we need to encourage young girls and women to consider these opportunities. Tim Peake is a fantastic ambassador for space and I have great respect for what he has already done in a short period of time, but let us imagine the impact if he had been Tina Peake and that message had gone out to young girls and women about such opportunities. When it comes to encouraging young girls and women into engineering just now, there are clear systemic problems in our culture that must be tackled. I call on the Government to join me and others to make sure that we change this attitude over the coming years.

Some 11% of engineers in the sector are women, but 21% of engineer graduates focused on the sector are women. This is the lowest percentage female employment rate in the sector in Europe, and we have the lowest retention rate in Europe. That is at a time when there are significant skills shortages at every level of the industry.

We have heard that many people are not aware of the opportunities in the space or the aerospace sector. I was delighted yesterday to meet Bridget Day, the deputy programme director for the national aerospace technology exploitation programme. I crave your indulgence, Madam Deputy Speaker, because I would like to read something she sent to me, at my request. She said:

“I have worked as an Engineer in the Aerospace industry for nearly 40 years. I worked for 30 years in the supply chain for a heat exchanger manufacturer in Wolverhampton, starting as a graduate apprentice and becoming Engineering Director. In my personal experience there has been little progress in encouraging women into engineering. I currently lead a team of engineers helping aerospace supply chain companies with new technology”—

within NATEP, as I have said. She continues:

“In a team of 24 there is only one other woman”,

That is a shocking figure. She continues:

“I know that engineering is considered difficult, dirty, and dying by the general public. This means that parents and teachers often encourage young people away from engineering, thinking that industry is something in the past and not for the future. The increasingly ‘green’ views of our youth are annoyed with industry building on green belt land and taking priority over wild life. So the reputation of industry publicly is not what my experience is. I have had a very varied working life, every day something different, everyday keeping me interested in solving problems with new ways of thinking, new materials, new possibilities. The amount of new possibilities is better than ever before and NOW”—

she capitalised it—

“is a great time to become an engineer. We are very short of engineers. As a woman in engineering I am often the only woman in the room, usually only 5% are women even at a large event. There is an assumption that I am the secretary and not that I am the boss. My reputation is never assumed, like a man’s often is, I always have to earn it.”

[Jim Shannon]

If I had been allowed to ask two questions at Women and Equalities questions this morning I would have raised this issue. The Government need to target girls-only schools and introduce the STEM industries, including engineering, to those girls.

[Drew Hendry]

I thank the hon. Gentleman for his substantive point about engaging young girls and women with these industries, and I absolutely subscribe to that view. As I have said—I will continue to repeat it here until we get it right—this is an issue that we need to tackle together to ensure that girls are able to take advantage of these opportunities.

Hand Hygiene: NHS

Jim Shannon Excerpts

Wednesday 13th January 2016 Westminster Hall

[Jim Shannon (Strangford) (DUP)]

It is always a pleasure to serve under your chairmanship, Sir Alan. It was especially nice to hear the hon. Member for Amber Valley (Nigel Mills) introduce the debate, and it is good to participate in it. I would like to give some personal knowledge and put forward some viewpoints.

I congratulate the hon. Gentleman on so succinctly setting the scene for the rest of us to follow. To add a bit of background to the debate, patients in the NHS today have a 6.4% chance of catching an infection in UK hospitals. There are 300,000 healthcare-acquired infections annually, of which 5,000 result in mortality. We cannot ignore the mortality rate—5,000 people dying in our hospitals is 5,000 too many. If the figure was one, that would be one too many. If we can take steps to prevent those deaths, we should do so.

Although our figures are below the European average, many other developed countries perform better, including the United States at 4.5%, Italy at 4.6%, Slovenia at 4.6% and Norway at 5.1%. I know that the Minister will address that in his response, but if the States, Italy, Norway and Slovenia can do it better, I am sure that we can achieve their levels, which would be a two percentage point drop or thereabouts from our current figure.

Not all healthcare-acquired infections are preventable, but it is believed that approximately 30% of them could be avoided by better application of existing knowledge and realistic infection control practices. Hand hygiene is an essential component of that.

I remember when my brother was in an accident. He liked racing motorbikes, but unfortunately 11 years ago he had a very serious accident that resulted in him being in a coma and in intensive care for some 19 weeks, followed by 2 years of rehabilitation. Whenever we visited him in the Royal Victoria hospital in Belfast, we all had to wash our hands. He was not able to respond to us at that stage, but his family and other people who knew him wanted to go and see him because of the severity of his injury. The nurse was clear: she said, “You have to wash your hands every time you go to that bed, because the risk of infection for someone in that extreme circumstance is very real.” Every time we left the bed and went outside the ward, we had to wash our hands before we went back to the bed—that was clearly outlined.

To me it was clear: we do that because we want to visit the person in the bed, but we may unwittingly have infections on our hands. The hon. Member for Bridgend (Mrs Moon) spoke earlier about sneezing. Unwittingly, we cover our mouth with our hand and then rub our hands. Then we might stick our hands in our pockets and rub them on the pockets. Even when using a hanky, there will still be infection on the hands. That is the point I am trying to make. It is clear that we have to do something.

The infection prevention and control sector claims that basic hand hygiene standards are not being met on many NHS wards. If that is the case, a clear guide needs to be given to those on wards to ensure compliance. The Deb Group claims that although 90% to 100% compliance with hand hygiene standards was reported by UK hospitals—it is easy to say that—the true figures are between 18% and 40%.

As health is a devolved matter, I have asked the Minister responsible for health back home questions on MRSA infections in hospitals, because even though we have few infections, it is clear that something needs to be done. Back home—it is probably the same elsewhere—many would say, “If you’re ill, be careful in hospital, because you have people with open wounds and people whose immune systems are down. If you bring in your colds, flus and coughs, or whatever it may be, that can have an impact.”

Deb also argues that the data collection method is flawed and that direct observation artificially inflates compliance, as nurses observe colleagues meeting the requirements and undertake a tick-box exercise. There needs to be more than that. NICE issues guidance on hand-washing in hospitals and encourages strict hand-washing practices, but it does not include a demand that accurate data be recorded. We want to ensure that that happens. If we record the data, we are making an effort and, if we are doing that, we are washing our hands. There may be some weight to Deb’s concerns, and that should be extremely worrying for all of us.

Good hand hygiene practice in hospitals is the single most effective way to prevent the spread of infection, and we should take action to ensure that more effective records of hand-washing on NHS wards are made in future. That is a simple yet effective way of making our hospitals safer, and with the recent growth in antimicrobial resistance we need to act sooner rather than later to ensure that poor hand hygiene does not further increase the severity of HAIs.

We have had an extensive hand hygiene strategy in Northern Ireland since 2008, and although some problems persist—in all honesty, we cannot stop all infections—we have seen results from simply adopting a thorough hand hygiene regime in our hospitals, with education on the importance and effectiveness of hand hygiene being an essential part of the Department of Health, Social Services and Public Safety’s regional infection control strategy. Like in Scotland and in some individual trusts, we are taking action to address the issue.

Accurate records are the starting point for addressing the problem. There are many examples across the world, but a recent three-year pilot in a hospital in South Carolina in the United States of America found that once staff were trained in how to use electronic hand monitoring systems, compliance with best practice increased and MRSA rates dropped. That saved the hospital $433,644 from April 2014 to March 2015. There was therefore also a financial advantage, and although that is not the reason to do it, it is an example of what can be done to stop infections and address costs.

As we seek to have a more streamlined and cost-effective NHS, those are the sorts of approaches we need to look into. Indeed, the introduction of such a system at Burton Hospitals NHS Foundation Trust drove up hand hygiene compliance by up to 50% in just three months. That is an example from this country, which shows what we can do if we put in the effort.

With 5,000 people dying each year as a result of HAIs, it is clear that action must be taken. With resistance to antimicrobial treatment increasing, we need to get on top of the issue before it is too late. Hand hygiene is the simplest and most effective way to do that, so let us make sure hospitals are doing that right and doing it well.

[Sir Alan Meale (in the Chair)]

We now move to the Front-Bench Members, and we have only until 5.30 pm. I therefore ask Members to be succinct. Minister, if it is possible, could you give a minute or so at the end to the Member who moved the motion to allow him to wind up the debate?

Swine Flu Vaccination: Compensation

Jim Shannon Excerpts

Tuesday 12th January 2016 Westminster Hall

[Stephen Twigg (Liverpool, West Derby) (Lab/Co-op)]

I beg to move,

That this House has considered the compensation for people with narcolepsy and cataplexy linked to swine flu vaccination.

It is a pleasure to serve under your chairmanship, Mr Chope. I thank Mr Speaker for allowing this debate on an important issue, and I thank the Minister for being here to respond to the concerns that I will raise on behalf of my constituent, Lucas Carleton.

I begin by saying something about vaccinations in the broad sense. We are fortunate in this country to have a robust and comprehensive vaccination policy. The policy has saved countless lives since its incarnation almost 100 years ago. Through our vaccination programmes, and those of other nations, we have successfully eradicated diseases such as smallpox across the world, and have reduced the number of people affected by polio by something like 98% over the past three decades. To this day, the advice from mainstream medical professionals and the national health service is that everyone should be vaccinated, not only to protect themselves but for the wider benefit of the communities in which we all live.

Historically, we have seen the tragic consequences of terrible epidemics that vaccinations can protect us against. For example, during the ’20s and ’30s, Spanish flu killed more people than the first world war had. Vaccinations, which are often brushed off in our everyday lives as a painful exercise, save thousands of lives a year, reducing human suffering and misery on a huge scale.

There is no serious scientific debate among mainstream scientists about the benefits of vaccination to public health—medical advice is clear that vaccination is one of the most successful and cost-effective public health measures—but vaccination is not without controversy. There have been a small number of instances when vaccinations have been responsible for adverse reactions, causing sometimes long-term and sometimes irreversible problems. I stress that that is rare, but tragically it is the reason we are here today.

During 2008 and 2009 there was a global swine flu pandemic, also known as the H1N1 pandemic. The particular strain of flu originated in Mexico, but it quickly spread, leading to the World Health Organisation issuing its first ever “public health emergency of international concern” declaration. Cases were confirmed in 171 countries and more than half a million people are thought to have died as a consequence.

During the outbreak, the British Government decided to purchase enough swine flu vaccine to immunise the entire population with two doses, meaning that 120 million doses were ordered. Almost 99% of the vaccines that were given out were Pandemrix, manufactured by GlaxoSmithKline—GSK.

Vaccines, as with all pharmaceutical products, are subject to extensive clinical trials. However, it is recognised that during a pandemic the trials may not be as rigorous as they would otherwise be, because of the demand to safeguard lives. Completing mass trials can takes months or even years. For that reason, the European Union intervened and licensed Pandemrix for use within the EU, including the UK, without the completion of the normal rigorous trials. That was followed by advice from the UK’s Joint Council for Vaccination and Immunisation, which advised that the Government begin immunisation to protect against a swine flu pandemic in this country.

As a consequence of the speeding up of the licensing process by both the EU and national Governments, GSK was not prepared to supply the vaccine to Governments unless it was given indemnity from any liability. The UK Government gave GSK that indemnity. For a number of reasons, other countries were much more cautious about granting an early licence. For example, the Food and Drug Administration in the United States had a policy of not licensing adjuvant vaccines—that is where a substance is added to vaccines to increase the body’s immune response—without robust clinical trials demonstrating that they are safe. Adjuvant vaccines have additional chemicals that speed up the body’s immune reaction to the antigen, and it is considered that that sometimes increases the risk of adverse reactions. That possibility led other countries, such as Switzerland, to license Pandemrix only for adults and not for children.

Pandemic swine flu vaccinations were added to the Vaccine Damage Payment Act 1979 by the Vaccine Damage Payments (Specified Diseases) Order 2009 in September 2009. The vaccine was added to the Act for the duration of the pandemic campaign, which lasted from October 2009 to August 2010. The campaign ended when the Swedish and Finnish Governments expressed concerns about a vast increase in the number of paediatric narcolepsy cases in children under 10. The condition usually shows symptoms in those in the 15 to 30 age bracket. It was not until August 2010 that the Swedish and Finnish Governments discovered a link with Pandemrix. On 1 September 2010, Finland stopped vaccinating with Pandemrix. The UK Government discontinued the pandemic campaign from the same date, but encouraged GPs to continue vaccinating with Pandemrix where no seasonal flu vaccine was available.

[Jim Shannon (Strangford) (DUP)]

Figures indicate that one in 2,000 people have narcolepsy that is not related to vaccination. When it comes to compensation, how would the hon. Gentleman ensure that those who are vaccinated and are due compensation actually get it?

[Stephen Twigg]

The hon. Gentleman’s intervention is timely, because he raises the issue to which I now turn. Lucas Carleton is a young boy who lives in my constituency in Liverpool. On 17 January 2011, he was vaccinated with Pandemrix. He was seven years old at the time and was in good health. His mother, Pauline, asked her GP to vaccinate Lucas because a family friend had recently been very ill with swine flu and, perfectly understandably, she believed it was a responsible step to get her son vaccinated. A week or two after Lucas received the vaccination, he began to experience excessive daytime sleepiness, which is a common characteristic of narcolepsy. He also started falling when he laughed or got excited, made strange facial expressions and experienced a loss of control of his tongue. That is known as cataplexy and is a common symptom of narcolepsy. After two to three weeks, Pauline sought medical help from a GP and Lucas was taken to hospital on a number of occasions. In August 2011, he was diagnosed with narcolepsy.

Narcolepsy is an incurable neurological disorder that until 1999 was classified as a psychiatric condition. Its main symptoms involve excessive daytime sleeping, hallucinations, sleep paralysis, temperature control problems and cataplexy. Cataplexy is a side symptom of narcolepsy that causes involuntary muscle relaxation brought on, for example, by laughing or anger. Narcolepsy begins in the hypothalamus, the part of our brain that controls our autonomic nervous system, which involves processes such as breathing and the regulation of the heart. Narcolepsy occurs when the brain cells that produce neurotoxins in the hypothalamus are destroyed, either through a trauma or through the body’s immune system mistaking those cells as foreign bodies.

The Department for Work and Pensions has accepted that the Pandemrix vaccine is capable of causing narcolepsy in children. It has also accepted that, in many cases, Pandemrix did in fact cause narcolepsy in children. However, it disputes that narcolepsy amounts to a severe disability. That is an issue on which the DWP has been defeated in court, but I understand that it is appealing against the decision. Herein lies the issue: the 1979 Act recognises that there can be adverse reactions to vaccines that can cause severe and irreversible damage to patients. Since the Act was passed, around 900 people have been awarded compensation, which is a very small number when compared with the 650,000 children vaccinated every year. Compensation can range from £120,000 into the millions.

The pandemic swine flu vaccine was part of the 1979 Act from September 2009 until it was removed by the Vaccine Damage Payments (Specified Disease) (Revocation and Savings) Order 2010. That is preventing Lucas from claiming compensation, as he had the vaccine administered outside that period, in January 2011. If the pandemic swine flu compensation period was simply extended to April 2011, Lucas and others who had adverse reactions could claim compensation for the reaction to the vaccine.

Oral Answers to Questions

Jim Shannon Excerpts

Tuesday 5th January 2016 Commons Chamber

[Alistair Burt]

Herbal products are slightly beyond my normal portfolio remit, but anything that assists in social care and makes people feel better and can add to their vitality and wellbeing is to be welcomed. I am sure in many local areas they are taken extremely seriously.

[Jim Shannon (Strangford) (DUP)]

I thank the Minister for his response. Integration and improving care outside of hospitals is just one way we can revolutionise the health service. Will he outline any links his Department is exploring between reducing pressure on A&Es and using care provision outside of hospitals to facilitate reducing that pressure?

[Alistair Burt]

Absolutely, and a number of the pilots and pioneer programmes are doing just that. Early results from the living well programme in Penwith in Cornwall show a 49% reduction in non-elective admissions to hospital and a 36% reduction in emergency admissions to hospital. So the hon. Gentleman is right: better social care and better integration may have, and should have, an impact on hospital admissions and make sure people are receiving the most appropriate care in the most appropriate place.

Victims of Contaminated Blood: Support

Jim Shannon Excerpts

Wednesday 16th December 2015 Commons Chamber

[Jim Shannon (Strangford) (DUP)]

I thank the Minister for her response to the urgent question. Brian Carberry from County Down contracted hepatitis C from contaminated blood in July this year. Compensation is always important, but the really important issue for those affected is that it is not enough when a problem is health related. What discussions has the Minister had with the Northern Ireland Health Minister, Simon Hamilton, to tackle this issue?

[Jane Ellison]

My officials are working closely with their opposite numbers in all the devolved Administrations. As we move towards publication of the consultation, I will look to communicate directly with my opposite numbers in the devolved Administrations and pick up all these points.

Specialist Neuromuscular Care and Treatments

Jim Shannon Excerpts

Tuesday 15th December 2015 Westminster Hall

[Jim Shannon (Strangford) (DUP)]

It is a pleasure to speak in this debate. It is always a pleasure to follow the hon. Member for South Down (Ms Ritchie), who made an impassioned plea on behalf of her constituent. Every one of us has constituents who suffer from Duchenne muscular dystrophy and other diseases and problems, so it is always good to make a plea on behalf of them in this Chamber. As always, it is good to see the Minister and the shadow Minister here.

I congratulate the right hon. Member for Chesham and Amersham (Mrs Gillan) on setting the scene for us all. She clearly outlined the issues, and asked questions of the Minister that we all endorse and support. I thank all other Members who have spoken. I am my party’s spokesperson on health, and I hope to find out about promising developments on the mainland that can be taken back to Northern Ireland, and that thoughts from Northern Ireland can be explained to the Minister. Perhaps the combination of the two can help us to look forward together, in ways that are to our advantage.

As other hon. Members have said, there are some 60 different types of neuromuscular condition, and it is estimated that around 60,000 to 70,000 people in the UK live with neurological conditions that affect their muscle function. Duchenne muscular dystrophy has been mentioned in particular. A couple of my constituents have that condition, and I am aware of the issues. At an event at the Methodist central hall across the way, people with the condition from across the United Kingdom of Great Britain and Northern Ireland clearly explained their needs, the issues—such as the massive advances in medical technology—and the best approaches. There are different levels of Duchenne, and what is medicine for one may not be medicine for another; that is the point I am trying to make.

In Northern Ireland, an estimated 1,600 people in the Southern Health and Social Care Trust area alone are diagnosed with neurological illnesses each year. That is equivalent to the number diagnosed with a major cancer; the conditions we are debating are of as great a relevance as some better-known ones. An estimated 34,000 people in Northern Ireland suffer from a disabling long-term neurological or neuromuscular condition such as epilepsy, multiple sclerosis, Parkinson’s disease, or one of the rare disorders such as motor neurone disease or muscular dystrophy, including Duchenne muscular dystrophy. Neurological symptoms such as headaches are one of the most common reasons for seeing a general practitioner, and they account for up to 8% of emergency department visits.

Last year, a new dedicated out-patient centre for neurology, with some responsibility for neuromuscular issues, was opened in Northern Ireland. That has been a positive development in the Province, helping with the nationwide momentum for access to treatment, and better treatment, for those living with neurological conditions. The new facility helps us to move towards meeting some of the latest standards in caring for people with long-term neurological and neuromuscular conditions. Since it opened, feedback has been very positive. Improved access to a modernised facility makes life much easier for patients and greatly improves their overall experience of their care.

I understand that the proposed multidisciplinary team will include neuromuscular consultants, neuromuscular physiotherapists and speech and language therapists, along with other care professionals. One of the key service outcomes, which I welcome, is that all patients with long-term neurological conditions have an individual care plan. The hon. Member for Romsey and Southampton North (Caroline Nokes) commented on access to wheelchairs; it is important for each individual to have a wheelchair that suits them. That might seem a small thing to some people, but to the patients it is massive. With 60,000 to 70,000 people in the UK living with neurological conditions, we must take those conditions seriously and prioritise our responsibility to those living with them.

A landmark decision could end the agonising wait for the delivery of the treatment that we are talking about to all those eligible to benefit in England, Wales and Northern Ireland. For those in Northern Ireland who benefited from the dedicated out-patient service I mentioned, I am sure this would be an additional boost. Nationwide, the momentum is now in favour of those living with neurological conditions. That may not always be how it feels, but there is a step forward, and we have to look at that, and at how to deliver that better. Although the move is very well intentioned and welcome overall, concerns have been raised and reservations expressed.

I know that the Minister will respond to what has been said about the NICE conditions. Lately he seems regularly to make particular reference to NICE in responding to debates in Westminster Hall and the main Chamber, and I think that is what Members are interested in. There is a need for a specific NICE response. It has asked for further clarification from PTC Therapeutics of the degree of benefit that its drug Translarna provides in the treatment of a type of Duchenne muscular dystrophy. DMD is one of a group of muscular dystrophies, which are inherited genetic conditions that cause the body to produce too little dystrophin, a substance crucial for muscle functioning. Seeing some of the young patients who have the condition focuses one’s attention quickly on how critical the availability of the medicine is. The condition leads to changes in the muscle fibres, which gradually weaken the muscles, resulting in an increasing level of disability. The decline in physical functioning in DMD leads to respiratory and cardiac failure and eventual death, usually before the age of 30.

Ataluren is the first licensed treatment for DMD that addresses the loss of dystrophin, the underlying cause of the condition. It has a conditional marketing authorisation in the UK for the treatment of DMD. The families of children affected, and Muscular Dystrophy UK, have campaigned for NHS England to make the drug available, since it became the first EU-approved drug for tackling Duchenne muscular dystrophy last August. The condition affects 2,500 people in the UK, causing increasingly severe disability and cutting lives short. It would be useful if the Minister and his Department could address NICE’s concerns, as it has asked questions. The right hon. Member for Chesham and Amersham referred to NICE and outlined four or five questions. I think that the focus that will emerge from the debate will be on how to improve the NICE guidelines and improve access to drugs throughout the United Kingdom of Great Britain and Northern Ireland.

Whenever I attend health debates in Westminster Hall, I ask whether we can have not just a regional strategy but a UK-wide one, bringing Northern Ireland, Scotland and Wales together. Will the Minister consider that? The four regions can benefit from each other’s knowledge. Collectively, we can do better.

Student Nursing (Finance)

Jim Shannon Excerpts

Monday 14th December 2015 Commons Chamber

[Wes Streeting (Ilford North) (Lab)]

I am grateful for this opportunity to lead my first Adjournment debate on the serious issue of finance for student nurses and midwives.

I have a long-standing interest in the issues. I spent much of my career outside this place working for a number of charities to widen access to higher education and to tackle broader educational disadvantage. As deputy leader and cabinet member for health and wellbeing in the London borough of Redbridge, I became acutely aware of the challenges facing frontline staff and managers in both of the NHS trusts that serve my constituents in Ilford North. I am also a proud supporter of Unison and draw Members’ attention to my declaration of interests. I am grateful to Unison, the National Union of Students, of which I am a former president, and many other organisations for their assistance in drawing together the evidence for this evening’s debate.

With just a few lines in the autumn statement, the Chancellor announced the biggest shake-up in the funding of nursing, midwifery and allied health subjects since the Health Services and Public Health Act 1968. By scrapping student bursaries and charging them tuition fees, the Chancellor is passing on the full cost of training to these essential frontline staff for the first time. The scale and potential consequences of his decisions merit further parliamentary scrutiny and public debate, and I hope that tonight will provide the first of many opportunities for that debate to take place.

Nursing and midwifery students currently pay no tuition fees for their studies and receive a non-means-tested grant of up to £1,000 and a means-tested bursary of up to £3,191 to help with the costs of living while they study and train. That is significant because students on both courses are required to work throughout their degrees in clinical practice, where they are subject to the full 24-hour care cycle. They work evenings, nights and weekends. Many will spend 60% of their degree doing that, with nurses required to work at least 2,300 hours across their degree. Even with the current levels of financial support in place, many struggle to make ends meet. Their courses are longer, their holidays are shorter and their placements are demanding. Those who do paid work outside their course can end up working more than 60 hours a week as a result, and they should not be expected to do so.

There has been a public outcry at the planned loss of the NHS bursary, but the Government’s plans go even further. Nursing and midwifery students will not only lose their grant and bursaries for maintenance; they will be expected to take out loans to pay for their tuition fees for the first time. These changes will burden students with eye-watering debts of at least £51,600, which they will begin to pay back as soon as they graduate, because nurses currently earn a starting salary just above the repayment threshold, which, shamefully, is now to be frozen at £21,000. As a result, nurses will on average take a pay cut of £900 a year to meet their debt repayments. That is no way for Ministers to treat the people who form the backbone of the NHS.

Given that the Government see fit to charge students for the cost of their tuition, will the Minister confirm whether he intends to pay student midwives and nurses for the hours they have to put into staffing our hospitals? If a private sector company tried to get workers to work long shifts and to pay for the privilege of working those long shifts while training, they would rightly be condemned. We should be no less outraged by what Ministers propose for nurses and midwives.

The impact of the changes will be felt beyond nurses and midwives; physiotherapists, occupational therapists, dieticians, chiropodists, podiatrists, radiographers, paramedics, prosthetists and other allied health professionals stand to lose out. We are not talking about the highest-paid people in this land; this assault on the living standards of key public sector workers is rightly causing outrage among NHS staff and members of the public who cherish the work they do on our behalf.

Given the scale and significance of the reforms, it is outrageous that the Government chose to sneak them out in the autumn statement. The Chancellor’s statement made an oblique reference to replacing

“direct funding with loans for new students”.—[Official Report, 25 November 2015; Vol. 602, c. 1363.]

The policy decision on page 126 of the Blue Book merely says:

“Students studying nursing, midwifery and allied health subjects from September 2017 will be moved on to the standard student support system, with the details subject to consultation.”

As the Government have placed so little information in the public domain so far and higher education institutions and potential applicants are already turning their minds to the 2017 admissions round, I hope that the Minister can shed some light on the details this evening. Will he confirm that the Government will consult on the principle of the policy changes, not merely on their implementation? What is the full timetable for the decision from consultation through to implementation?

What analysis have the Government conducted of students in receipt of NHS bursaries for tuition and maintenance costs? Will they publish an equality impact assessment for the proposals? What research have the Government conducted into the financial hardship facing existing nursery and midwifery students and students of allied health subjects?

Why do the Government think it is fair that students from the most deprived backgrounds should have their grants taken away while some of the wealthiest people in our society receive tax cuts? How much of this debt do the Government expect to write off because those indebted by these reforms are unable to repay them in full?

Which Department will meet the cost of servicing the RAB—resource accounting and budgeting—charge for the student loan debt: the Department of Health or the Department for Business, Innovation and Skills? What are the Barnett consequentials for health education budgets in Northern Ireland, Scotland and Wales, where different arrangements are in place?

[Jim Shannon (Strangford) (DUP)]

I thank the hon. Gentleman for bringing this issue before the House. I understand that 56,000 students on the mainland, including Scotland and Wales, may be in debt as a result of this change. In Northern Ireland, the Health Minister has committed himself to continuing the bursary. We are doing that in Northern Ireland; perhaps the rest of the United Kingdom should do the same.

Anti-TNF Drugs

Jim Shannon Excerpts

Wednesday 9th December 2015 Westminster Hall

[Fabian Hamilton (Leeds North East) (Lab)]

I beg to move,

That this House has considered prescription of anti-TNF drugs.

It is a pleasure to serve under your chairmanship, Mrs Main. I am grateful for the opportunity to speak about NHS prescription of anti-tumour necrosis factor drugs, a subject on which I have become somewhat familiar since I was contacted more than two months ago by my constituent, Samara Ullmann.

Before I move on to why I requested the debate and to define what anti-TNF drugs are and their uses, it may be helpful to give you, Mrs Main, the Minister and other Members present the background as to why this specialist medication will make such a difference to my constituent and so many others.

Samara Ullmann, who is now 29 years old, was born in my constituency in 1986. At the early age of just two, her parents noticed that she was walking with a limp. Worried about her clear inability to walk without pain, her parents took her to her local GP, who referred her to Leeds general infirmary where she was diagnosed with a condition known as juvenile idiopathic arthritis. The terrible condition affected both of little Samara’s legs, her wrists, her ankles and her knees. Her parents were told by the hospital that it was likely that she would have to be in a wheelchair by the time she reached the age of 10. From the age of two and until she was six, she had to wear splints on both her legs.

Professor Anne Chamberlain supervised Samara’s treatment over the next few years. During Samara’s visits to Leeds general infirmary every three to four weeks she was given hydrotherapy, physiotherapy and a cocktail of drugs. Her parents were told that little else could be done for her, which was confirmed by some of the country’s top rheumatologists.

From the age of six, Samara started having problems with both her eyes, which developed uveitis, a common effect of JIA. By the time she was seven, a cataract had developed in her left eye and was removed, but it was left considerably weakened so that, by the time she reached the age of 11, she had completely lost the sight in that eye. Fortunately, her right eye continued to function normally, although when she reached the age of 14 she needed laser treatment on that good eye and was understandably frightened that she would be left completely blind.

The JIA improved considerably by the time Samara reached 17, but sadly her left eye had to be removed because it was both blind and painful. After three months, she was fitted with a prosthetic glass eye, which fortunately is able to move to a limited extent with her functioning eye. The Minister may be able to imagine the terrible effect that all of that had on a teenage girl growing up in the early part of this century. Her self-confidence was badly damaged, too.

As the arthritis gradually abated, Samara was left with a common consequence of the condition, refractory uveitis, which often causes blindness even with the best treatments currently available. Her right eye—her only eye—is now severely affected. So far, despite a paralysed iris, a stuck-down pupil and a developing cataract in her remaining eye, her sight has been partially protected by the use of a drug called mycophenolate, which together with methotrexate is commonly used to treat uveitis.

Those drugs impair the white blood cells that promote the inflammation that causes uveitis. However, despite treatment with those drugs over the past eight years, the vision in Samara’s only eye continues to deteriorate. That is why her eye specialist at Calderdale Royal hospital in Halifax, Mr Teifi James, believes that in order to save her sight, she needs to be prescribed an anti-TNF drug such as Humira—adalimumab.

An anti-TNF drug is a monoclonal antibody that specifically targets tumour necrosis factor alpha. Because of the way in which it is manufactured, it is called a biologic. TNF is involved in causing inflammation in a number of autoimmune and immune-mediated disorders. Those diseases probably cause too much TNF to be produced, modifying the body’s immune response and causing inflammation. Anti-TNF drugs reduce the amount of TNF in the body. They are expensive and may have side effects that could be severe, but, with appropriate monitoring and care, such effects are rare. In fact, they are much less common than the many problematic side effects of corticosteroids.

[Jim Shannon (Strangford) (DUP)]

I thank the hon. Gentleman for bringing this issue to Westminster Hall. The Minister will be seeking to improve the success rate of anti-TNF drugs. Many universities across the United Kingdom are looking at how to improve medication for those with eye ailments. We have two in Northern Ireland, which are Queen’s University Belfast and, in particular, Ulster University—

[Mrs Anne Main (in the Chair)]

Order. Will the hon. Gentleman keep his intervention brief, please?

[Jim Shannon]

Does the hon. Gentleman agree that that is a good idea?

[Fabian Hamilton]

I thank the hon. Gentleman for that intervention. He is right. The more studies carried out across the country at university level, the better it will be for patients suffering from refractory uveitis.

The anti-TNF drugs switch off the molecule that creates the inflammation in the first place and are therefore far more effective than corticosteroids in cases such as Samara’s. I am sure that Queen’s University Belfast and many others can confirm that.

Last year, Samara married her fiancé, Ben, and the couple now want to start a family. However, it is not at all advisable for her to become pregnant while taking mycophenolate, because it may well cause a miscarriage or birth defects. An anti-TNF drug could allow her to retain her eyesight and probably to conceive safely and be able to see her child grow up.

Let me move on to why adalimumab or infliximab should be available immediately on NHS prescription for adults with sight-threatening uveitis. I am aware that the National Institute for Health and Care Excellence is about to conduct a multiple-technology appraisal of adalimumab and infliximab and that responses to the draft must be received by 16 December—this time next week. From my conversations with Teifi James, one of the country’s leading eye surgeons, and from my research into that treatment it would seem that drugs such as Humira are highly effective in the treatment of uveitis, so much so that researchers in the Sycamore trial in Bristol, to which the Minister referred in his letter to me of 4 November, have stopped recruiting to it because the children being treated are doing so well on the drug. However, NHS England did not take that into account when it made its most recent decision on the use of adalimumab and infliximab for the treatment of adult uveitis alone.

According to Mr James, approximately 120 patients with sight-threatening uveitis are waiting for anti-TNF treatments in England, whereas patients in Scotland currently have access to adalimumab and infliximab. Treatment using Humira costs just under £10,000 a year per patient, which means that approval of the use of this drug for treating refractory uveitis alone would cost no more than £1.2 million a year.

Cystic Fibrosis

Jim Shannon Excerpts

Tuesday 8th December 2015 Westminster Hall

[Jim Shannon (Strangford) (DUP)]

It is a pleasure to serve under your chairmanship, Sir Edward. It is also nice to see the Minister in his place again—whatever the debate might be, there are few for which the Minister and I are not in the same room at the same time.

I thank the hon. Member for Dudley North (Ian Austin) for bringing this important issue to Westminster Hall. It affects my constituents and I am here to speak on their behalf—this is the place for us to do that as elected representatives. As he mentioned in his introduction, in Northern Ireland we have had some good news, with money set aside for rare diseases. Any approach to such diseases needs to be innovative and to take into account all those who contribute, be they academics, researchers or hard-working charities who provide support for those suffering from cystic fibrosis and their families.

I also commend the right hon. Member for Chesham and Amersham (Mrs Gillan) and the hon. Member for York Central (Rachael Maskell) who have spoken. They are doughty campaigners on behalf of those who have Duchenne and on many other issues. It is good to see them in their places and making valuable contributions.

We are surely duty-bound to support and fund those who fight for the sufferers and those developing new treatments. The debate is very much about how we develop new treatments and move forward.

[David Simpson (Upper Bann) (DUP)]

I also congratulate the hon. Member for Dudley North (Ian Austin) on bringing the debate. Does my hon. Friend agree that pharmaceutical companies need to be sent a message that their work in research is not about large profits; it is about curing rare diseases? We saw that difficulty whenever we approached pharmaceutical companies on meningitis B: some companies held out for large profits at the expense of people who were suffering.

[Jim Shannon]

I thank my hon. Friend for focusing on the pharmaceutical companies. They can do a great deal and there is also a role for Government and the NICE guidelines, which direct the direction in which pharmaceutical companies will proceed. The companies are driven not always by profit or margins; criteria also indicate to them what to do.

We should be ever mindful that people are suffering through no fault of their own, so we need to help them move forward. It is good to see facts and figures that show that, on average, a child born in the 21st century with cystic fibrosis will live for more than 50 years. There have been tremendous advances. The innovation and hard work done by charities and researchers is too often forgotten, but it has brought about real results, with new precision medicines treating not just the symptoms, but the underlying cause of the condition. We must go further in that direction. To be fair, cystic fibrosis is one condition that we are probably treating rather than solving at the moment, but we need to see a future where everyone with cystic fibrosis can live a life unlimited, which the facts show is more achievable today than ever before.

Unfortunately, precision medicines are expensive and, as my hon. Friend the Member for Upper Bann (David Simpson) said, it is difficult to predict the cost-effectiveness of new treatments. However, we need to get those treatments and try them out to move forwards. I understand that the Government are considering how we can speed up access to innovative treatments, which I think comes under the NICE guidelines. Will the Minister respond to that in his speech? There are proposals to approve new drugs provisionally while using real-world data to assess their benefits. I welcome that and look forward to seeing more of it.

May I put on record my thanks to the Northern Ireland Rare Disease Partnership under the chairmanship of Christine Collins, who happens to be one of my constituents? We have worked together over the years on this matter. Indeed, in the previous Parliament we spoke to the Under-Secretary of State for Health, the hon. Member for Battersea (Jane Ellison), in a private meeting. She was supportive and allowed us to make positive progress. As everyone knows, health in Northern Ireland is a devolved matter. The Minister there, my colleague, Simon Hamilton, has set aside about £3 million for the partnership, which shows there are positive approaches in Northern Ireland and a positive way forward. Perhaps that could be emulated across the whole of the United Kingdom of Great Britain and Northern Ireland.

It is estimated that one in 2,500 babies in the UK will be born with cystic fibrosis and there are more than 9,000 living with the condition. The facts are stark. It most commonly affects white people of northern European descent—it is much less common in other ethnic groups. Those are the facts, which in my constituency means that we are looking at virtually the whole populace. Other constituencies will have similar demographics, so it is concerning to hear that, but it is encouraging that research has advanced so much that we can pinpoint such factors so that we know where problems could arise.

Babies are screened for cystic fibrosis at birth using a heel-prick test as part of the NHS’s newborn screening programme. The NHS and Ministers responsible are taking correct steps to diagnose such conditions at an early stage. Treatment for cystic fibrosis is not curative, but it seeks to manage symptoms. Medications including steroids, antibiotics, insulin and bronchodilator inhalers are often used. Nutritional advice and physiotherapy for airway clearance are commonly part of management.

Cystic fibrosis patients may also be suitable for lung transplants. NICE provides a number of guidelines on specific treatments for cystic fibrosis, which it is currently updating. They are due to be published in 2017. On organ transplants, I believe that we should all be considered to be donors unless we say otherwise. The Welsh Assembly has taken steps to bring in that in Wales and such legislation is pending in other regions of the United Kingdom as well, but whenever we see stories about those who are managing but no more and for whom a lung transplant would be the beginning of a new life, perhaps we should emphasise the organ transplant system and find a method to make progress on that.

The hon. Member for York Central rightly referred to families. We focus on those who have cystic fibrosis, but let us also focus on those who support their loved ones at times of hardship and difficult health symptoms. I will also plead the case for Prader-Willi syndrome. I have a number of constituents who have it, but that is not unique by any means to my consistency; it is seen across Northern Ireland. We do not hear much about this, which is another muscular wasting disease and also an eating disease—it is an obsessive disease.

The right hon. Member for Chesham and Amersham talked about Duchenne muscular dystrophy. I have constituents who suffer from that and I have attended events just across the way with people from across the UK with it. It comes in different levels and types, but, as she said, there have been advances in medication. The Minister may refer to those in his reply, but we also need to focus on how we can help those families.

Recent developments show that innovation is working in advancing treatment of cystic fibrosis. I commend the Department for its work. I will also mention the hard work done by universities in partnership with private business and enterprise to come up with innovative ideas for new drugs. We can never underestimate the importance of what they do. Just as others speak highly of their universities, I do so of Queen’s University Belfast and Ulster University which are bringing forward innovative ideas for advances in medicine and other things. We could work well together with them on this.

I spoke earlier of the hidden or forgotten sector: the voluntary charities, of which there are many. Where would we be without them and their dedicated researchers? Such people often dedicate their lives to helping humanity overcome disease. The Cystic Fibrosis Trust is just one example. It is the largest charity funder of cystic fibrosis research in the UK. Last year it invested more than £3 million in groundbreaking research and it plans to invest a further £3.5 million by the end of this financial year. By adding our support and funding where possible, we can add to the great work being done and make a real life-changing difference for those with cystic fibrosis and their families.